オプションチェーンは、Hagertyの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Hagertyの市場センチメントを評価します。.

Hagerty (NYSE:HGTY) 株価情報, オプションチェーン

Hagerty

Hagerty Inc is a provider of specialty automotive insurance. The company underwrites, sells, and services classic car and enthusiast vehicle insurance policies. Substantial revenue is derived from Commission and fees. Geographically it serves Europe, Canada, and the United States.

Hagerty Inc

Stephens &amp; Co. analyst Russell Gunther reiterates SmartFinancial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMBK#NYSE">SMBK</a>) with a Equal-Weight and maintains $31 price target.

News

Price Target

Reiteration

Analyst Ratings

SMBK

Stephens & Co. Reiterates Equal-Weight on SmartFinancial, Maintains $31 Price Target

Gulf Resources, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GURE#NASDAQ">GURE</a>) ("Gulf Resources," "we," or the "Company"), a leading manufacturer of bromine, crude salt, and specialty chemical products in China, today issued a press release providing an update on its bromine segment.
In 2024, our bromine segment reported a net loss of $8,200,236 on revenues of $5,549,815. Two primary factors contributed to this loss. First, bromine prices were significantly depressed. The average price for 2024 was RMB 17,561, representing a decline of 27.1% from 2023 and 67.3% from 2022.
Due to these unfavorable market conditions, the Company intentionally scaled back bromine sales. As a result, sales volume dropped by 71.7% year-over-year. This sharp decline in volume led to a substantial increase in the cost per tonne—up 83.4%—as fixed costs and overhead expenses had to be spread across a much smaller production base.
As demonstrated in the table below, the profitability of our bromine segment is highly sensitive to both market prices and production volumes. With fixed costs and overhead remaining relatively constant, a decline in either factor has a significant impact on the segment's financial performance.

GURE

Gulf Resources Reports $8.2M Net Loss On Revenues Of ~$5.55M In 2024 Bromine Segment As Depressed Prices And Strategic Sales Reduction Lead To 71.7% Volume Drop And 83.4% Cost Surge, Highlighting Sensitivity To Market Conditions And Fixed Overhead Impact; Says "For The Remainder Of 2025, At Current Levels, Our Bromine Segment Is Expected To Be Highly Profitable And Generate Strong Free Cash Flow"

BOCA RATON, FL, April 22, 2025 (GLOBE NEWSWIRE) -- Janover Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JNVR#NASDAQ">JNVR</a>) today announced that it has officially changed its corporate name to DeFi Development Corporation, reflecting its evolution into a crypto treasury vehicle designed for public market investors.
In connection with the name change, the Company will change its ticker to the symbol "DFDV" on the Nasdaq at a future date.
"This marks the beginning of a new chapter for the business," said Joseph Onorati, Chief Executive Officer of DeFi Development Corporation. "Our mission is to bring transparent, crypto-native capital allocation into the public markets — and this name change reflects that commitment."
To accompany the transition, the Company will also be launching a new website —&nbsp; <a href="https://www.globenewswire.com/Tracker?data=COrnc2nLIM8UR0LKJ1OSJhteToJH8AX95aRb-FyVzuyW2Dt2njlXuG6nOaMD-FpcAeV97aRmlIjxOyZKZfxQrwVNNlrymeQXZvSzB4w7i7g=">www.defidevcorp.com</a> — which will feature key treasury disclosures, including current Solana (SOL) balances, SOL per share ("SPS"), and other key metrics that provide public market investors with clear visibility into treasury positioning.
The name and future ticker change do not affect the Company's legal structure, business operations, or existing financial reporting obligations. Shareholders are not required to take any action in connection with the change.

JNVR

Janover  Announces Corporate Name Change To DeFi Development Corporation Reflecting Its Evolution Into A Crypto Treasury Vehicle Designed For Public Market Investors. Company Will Change Its Ticker To DFDV At A Future Date

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

OCEA

Ocean Biomedical Intends To Develop And Operate Select Power Assets With An Initial Focus On Data Center-Grade Infrastructure And Grid-Interactive Generation; Co. Will Also Allocate A Portion Of Cash Reserves Into Bitcoin And Solana

Stephens &amp; Co. analyst Andrew Terrell reiterates Cathay General (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CATY#NASDAQ">CATY</a>) with a Overweight and maintains $51 price target.

CATY

Stephens & Co. Reiterates Overweight on Cathay General, Maintains $51 Price Target

Advanced optical infrastructure delivers 20T capacity, automated management on 1,055 km Jakarta-Singapore link
PLANO, Texas, April 22, 2025 /PRNewswire/ --&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4409361-1&amp;h=2622403139&amp;u=https%3A%2F%2Fwww.rbbn.com%2F&amp;a=Ribbon+Communications+Inc.">Ribbon Communications Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBBN#NASDAQ">RBBN</a>), a leading supplier of real-time communications technology and IP optical networking solutions, today announced that PT Mora Telematika Indonesia Tbk ("Moratelindo") (IDX: MORA), one of Indonesia's largest telecommunication infrastructure and network providers, through Ribbon's local partner, has selected Ribbon's cutting edge technology solutions to fulfill their growing requirements for reliable, high capacity connectivity and seamless, automated infrastructure management. Ribbon is dedicated to assisting the world's largest service providers, enterprises and critical infrastructure operators in modernizing and safeguarding their networks and services.

RBBN

Ribbon Communications Chosen By Moratelindo For Enhanced Submarine Network Capabilities

Rigetti, in collaboration with Riverlane and the National Quantum Computing Centre (NQCC), has been selected as one of the winners of Innovate UK's Quantum Missions pilot competition. Leveraging Rigetti's quantum computer hosted at the NQCC, the £3.5 million Rigetti-led consortium aims to benchmark and enhance the quantum error correction capabilities of superconducting quantum computers — a requirement for achieving large-scale fault-tolerant quantum computing.

Contracts

RGTI

Rigetti Wins Innovate UK's Quantum Missions Pilot Competition; To Lead £3.5M Consortium Alongside Riverlane And The NQCC Superconducting Circuits Team

Earnings

ASRV

AmeriServ Financial Q1 EPS $0.12 Up From $0.11 YoY, Sales $14.05M Up From $13.69M YoY

SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce the initiation of supply chain activities by its wholly owned subsidiary Scienture, LLC to manufacture launch quantities of ArbliTM (losartan potassium) Oral Suspension, 10 mg/mL for the intended commercial launch of the product in July 2025. Scirenture, LLC's contract manufacturing partner, Saptalis Pharmaceuticals, LLC for ArbliTM has indicated to Scienture that Saptalis has the materials and capabilities to produce the batches and supply product inventory in time for the target commercial launch. In addition, Scienture, LLC has also entered into agreements with strategic partners for warehousing and distributing the product to the market through various wholesalers.
ArbliTM is meant for the treatment of hypertension in patients greater than 6 years old, for the reduction of risk of stroke in patients with hypertension and left ventricular hypertrophy and for the treatment of diabetic nephropathy in certain patients with type 2 diabetes. ArbliTM is the first and only FDA approved ready-to-use oral liquid losartan in the U.S. market.
ArbliTM is a novel proprietary formulation of losartan, a proven therapy for treating hypertension, which provides a tailored approach to patients that require or prefer an oral liquid option of losartan. Appropriate dosing is now easier, safe and effective, while providing the assurance of quality as an FDA-approved product. ArbliTM provides a safe and convenient option to patients requiring a liquid formulation and addresses the intrinsic risks associated with potential inconsistencies in the process of crushing tablets to extemporaneously compound losartan prescriptions. ArbliTM has two issued patents from the USPTO, which are also expected to be listed in the FDA Orangebook.
Losartan is classified as an angiotensin receptor blocker (ARB) for treating hypertension and is one of the highest prescribed molecules for this indication. Current products in the market containing losartan are available only as oral solids, which can be further compounded to a liquid formulation. ArbliTM is the first liquid formulation of losartan on the market that does not require compounding and has reduced dosing volume and long-term shelf life at room temperature storage. IQVIA data (MAT December 2024) indicates a total annual sales of approximately $292 million and a prescription volume of 68 million (TRx) for losartan in the US market.

Biotech

General

SCNX

Scienture Announces Manufacturing Launch Activities For Arbli Through Subsidiary Scienture, In Collaboration With Saptalis Pharmaceuticals And Strategic Distribution Partners, Targeting July 2025 Commercial Launch

Stephens &amp; Co. analyst Matt Olney reiterates Cadence Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CADE#NYSE">CADE</a>) with a Overweight and maintains $40 price target.

CADE

Stephens & Co. Reiterates Overweight on Cadence Bank, Maintains $40 Price Target

Fartcoin (CRYPTO: FARTCOIN) has surged past the key $1 milestone, eclipsing better-known meme coins and catching the eye of <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41879587/from-16000-to-18-million-in-unrealized-gainsmillionaire-bonk-doge-trader-shares-update-if-you-cant-hold-you-wont-be-rich">top traders across the space</a>. 
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Fartcoin (CRYPTO: FARTCOIN)</td>
<td>$1.06</td>
<td>$1.06 billion</td>
<td>+17.9%&nbsp;</td>
<td>+17%</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.1645</td>
<td>$24.5 billion</td>
<td>+2.4%</td>
<td>+3.3%&nbsp;</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001259</td>
<td>$7.4 billion</td>
<td>+0.1%&nbsp;</td>
<td>+5.5%</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Prominent trader Unipcs <a href="https://x.com/theunipcs/status/1914506572857827360">shared</a> that his Fartcoin long now sits at $5.1 million in profit, up from $3.2 million as of April 9. 
Heavily-followed crypto expert Joe McCann <a href="https://x.com/joemccann/status/1914416997812854968">called</a> Fartcoin the &#8220;best-looking chart in crypto right now,&#8221; while pseudonymous trader Cold Blooded Shiller <a href="https://x.com/ColdBloodShill/status/1914587407992619049">noted</a> it has cleared a four-month downtrend, confirming its first full trend reversal since January 2025.
Altcoin Sherpa set his next upside target at $1.30, although he cautioned traders to expect brief pauses or consolidations along the way. 
Despite ranking 62 by market cap, Sherpa believes Fartcoin has significant upside potential due to its rising brand recognition.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">$1.30 is next with a few pauses along the way imo for Fartcoin This is still pretty low market cap wise at #62, I think it still has a few x left given the mindshare <a href="https://t.co/3RjhyRNnXJ">pic.twitter.com/3RjhyRNnXJ</a>
&mdash; Altcoin Sherpa (@AltcoinSherpa) <a href="https://twitter.com/AltcoinSherpa/status/1914615221941100701?ref_src=twsrc%5Etfw">April 22, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Meanwhile, Dead Cat Bounce <a href="https://x.com/DCBcrypto/status/1914596430741746085">provided </a>a technical breakdown, noting Fartcoin initially failed to break its range high at the yearly open and started forming lower highs. 
But it defied broader market weakness, ultimately breaking above the range and validating a bullish breakout. 
He managed to secure a spot position on the retest, calling the chart "strong" as long as it holds above prior resistance.
Statistics: According to Grey BTC, whale accumulation <a href="https://x.com/greybtc/status/1914602482619081086">continues</a>, with one wallet scooping up $3.07 million worth of Fartcoin.
Fartcoin's 16% single-day rally brought it above $1 for the third time ever, something Dogecoin and Shiba Inu still haven&#8217;t achieved. 
Standing strong in 24-hour trading volume at the fourth position, Fartcoin has left behind Shiba Inu, Dogwifhat, Bonk and many others.
Over the past 30 days, Fartcoin is up 112.8%, while Dogecoin and Shiba Inu have posted negative returns.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/04/44901647/not-dogecoin-shiba-inu-heres-why-whales-are-piling-into-fartcoin">Not Dogecoin, Shiba Inu — Here&#8217;s Why Whales Are Piling Into Fartcoin</a></li>
</ul>
Image: Shutterstock

$DOGE

$SHIB

Dogecoin, Shiba Inu Struggle As Fartcoin Surges Past $1

U.S. stock futures were higher this morning, with the Dow futures gaining around 300 points on Tuesday.
Shares of Northrop Grumman Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) shares fell sharply in today&#8217;s pre-market trading after the company reported worse-than-expected first-quarter EPS and revenues. The company also lowered its <a href="https://www.benzinga.com/quote/NOC/earnings">FY25 EPS guidance</a>.
Northrop Grumman reported quarterly earnings of $6.06 per share which missed the analyst consensus estimate of $6.26 per share. The company reported quarterly sales of $9.468 billion which missed the analyst consensus estimate of $9.936 billion.
Northrop Grumman shares tumbled 8.5% to $485.99 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>USA Rare Earth, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAR#NASDAQ">USAR</a>) shares dipped 9.3% to $10.65 in pre-market trading. USA Rare Earth will release financial results for the first quarter, after the closing bell on Wednesday, May 14.</li>
<li>Tyra Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TYRA#NASDAQ">TYRA</a>) declined 7.3% to $8.40 in today's pre-market trading.</li>
<li>National Energy Services Reunited Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NESR#NASDAQ">NESR</a>) dipped 6.9% to $5.60 in pre-market trading.</li>
<li>Celcuity Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>) declined 6.1% to $9.81 in pre-market trading.</li>
<li>SITE Centers Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SITC#NYSE">SITC</a>) shares fell 5.7% to $11.01 in pre-market trading.</li>
<li>Halliburton Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) declined 5.7% to $20.67 in pre-market trading following first-quarter results.</li>
<li>Five Point Holdings, LLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FPH#NYSE">FPH</a>) declined 5.3% to $4.61 in pre-market trading. Five Point Holdings will hold a conference call to discuss its first quarter financial results on Thursday, April 24.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44896269/how-to-earn-500-a-month-from-3m-stock-ahead-of-q1-earnings">How To Earn $500 A Month From 3M Stock Ahead Of Q1 Earnings</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Movers

Trading Ideas

CELC

NESR

SITC

TYRA

USAR

Northrop Grumman Posts Downbeat Results, Joins Halliburton And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

<a href="https://www.globenewswire.com/Tracker?data=yfZ2eSHDjFlismVQ22s7M9ahGIsxc_c3JjmLemcisJobsa7peXhySiz3DFrXLtooq_g_f-kPedb-852zUon7n4qfGS2joB0T27fsCeHHKYYtw-aQJo35C-X1FD-BX-FCvZKlVgEPP51WycSwzCraxE1fTU-LuVNL9f5gb1jMK_KlfH7jsUwMxcGVsDdKfbInO7SPuLXztF4TCyZm3-Hv7-SU6ahOnQyaTE3rbNNQK5z7ZGUaeN9zQncx-ehsALJgmYNDdESneNf5OfsvcU8U-V3wN1JkJaKsPN9NYHEEpn0P3cC8zJB6CXCLVVSVPrXhKTAQWCCT41fQ4Y75_sB5364FIFW_kWoJF0Nxt6gjl-aTyM8QDlzBZ4lIyPwMj960SXfgwL2CMfNxSm9lWOuz5Fm8GCIYi29ve90WTSwBYLs=">Bio, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>), an AI-driven innovator of precision antibody therapies, today announced a licensing agreement with AstralBio Inc. for a preclinical first-in-class antibody targeting <a href="https://www.globenewswire.com/Tracker?data=2Ap9Z7U3HayJzgEw3tx13uO0r3yrphLjM4Fi4nyTVJEqF6LUdjUxq6W1UgaoCpDR75nPmjcAH8gb-akQ4d42b5HGP6n3FFxu1Qkm-WC59rkA-ng-syij9rLfgJySEkoIxhNkLegX__IsPydEZJE4NlyR2eXOPVvZOiUgxwB7AGnX2GiO65WX8MFHRXhdOEHFA3Dzvy-sBaE9Sn_-1m20PCjJDQaFHfLkGEPIZMSXjt3YHpCw2DMICI9FQYGVK_G907DW4sbDJM7sE6WUQhC2jzuivj8nFSylTCkdzLzgt45ZRPJL8w-PMf4g7QEEJ7CE">Activin E, which was discovered using iBio's patented Machine-Learning Antibody Engine</a>. Activin E is a promising novel therapeutic target whose inhibition is believed to induce fat-selective weight loss and offer protection against obesity and cardiometabolic disease. iBio plans to rapidly advance testing of the antibody in more complex models following preclinical studies that demonstrated strong antibody binding, inhibition of Activin E signaling and fat-specific weight loss in an obese rodent animal model.
The in-licensed antibody represents what iBio believes to be the first functional inhibitor of Activin E, a challenging, yet genetically validated therapeutic target playing a key role in regulating energy balance and fat distribution. Inhibiting Activin E-mediated signaling could offer a novel therapeutic strategy to reduce internal abdominal fat while preserving muscle mass—potentially reversing obesity, preventing diabetes, and improving overall cardiometabolic health. As one of several cellular components involved in cardiometabolic regulation, Activin E, along with amylin, GLP-1 and others, are part of a broader network of signaling pathways that have the potential to be targeted simultaneously to yield synergistic benefits for patients.
Using its proprietary Machine Learning Antibody Engine and advanced epitope engineering technology, iBio designed engineered epitopes representing five key regions of the Activin E protein. This approach led to the successful development of a molecule that fully blocks Activin E-mediated signaling and inhibits its function across multiple in vitro models. In vivo proof-of-concept was established in a rodent model of obesity, where the antibody induced fat-selective weight loss as a monotherapy and showed synergistic weight loss when added to a GLP-1 receptor agonist in <a href="https://www.globenewswire.com/Tracker?data=IC6CnWZUDTXt2k2kQcI4UJS1sr27bCIdXB-9lKCH8hUbHT9eSX6RDqG0dYhVJoP0JKTOGoC1X4gdoMxNyQ8ynAHTRfFgqQKESrJ9tavPegKHu6w_bc9eAAY8NIS3PlJpiOr4wMu1FUImPpFwVI8vsHJnGXMEZTaiaFlygE1a550MScR6WC_Is1iLv-scMHL1eGjJQKeszBIQMEDM0twrdJ-WOs-WEx9vGSAr96a0bJg=">recently published data</a> by iBio. iBio plans to present additional preclinical data of its antibody targeting Activin E at the International BMP Conference, taking place in Philadelphia, PA, from May 2–6.
"Our decision to license this Activin E-targeting functional antibody, a potentially first-in-class molecule, at this early stage reflects our firm belief in Activin E as a promising therapeutic target and our confidence in building upon the strong preclinical data we recently published," said Martin Brenner, Ph.D., DVM, iBio's Chief Executive Officer and Chief Scientific Officer. "This antibody represents a strategic expansion of our pipeline in cardiometabolic diseases and obesity and a significant step toward clinical development of a medication that can potentially offer meaningful benefits to patients."

IBIO

iBio, Announces A Licensing Agreement With Astralbio For A Preclinical First-In-Class Antibody Targeting Activin E

Fully Virtual Event Scheduled for June 27, 2025
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lineagecell.com%2F&amp;esheet=54240283&amp;newsitemid=20250422494799&amp;lan=en-US&amp;anchor=Lineage+Cell+Therapeutics%2C+Inc.&amp;index=1&amp;md5=4799d27d578473dc9ce41dd3ef438365">Lineage Cell Therapeutics, Inc.</a> (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, and the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.christopherreeve.org%2F&amp;esheet=54240283&amp;newsitemid=20250422494799&amp;lan=en-US&amp;anchor=Christopher+%26amp%3B+Dana+Reeve+Foundation&amp;index=2&amp;md5=768a206510831e902e4cb558fc0af8ca">Christopher &amp; Dana Reeve Foundation</a>, a non-profit organization dedicated to advancing innovative research and improving quality of life for individuals impacted by paralysis, are proud to collaborate and present the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.scisymposium.com&amp;esheet=54240283&amp;newsitemid=20250422494799&amp;lan=en-US&amp;anchor=3rd+Annual+Spinal+Cord+Injury+Investor+Symposium&amp;index=3&amp;md5=99f24f2f1e3c2e4fa81acd2e45ab6212">3rd Annual Spinal Cord Injury Investor Symposium</a> ("3rd SCIIS"). This year's event aims to bring together companies working in the development of treatments for SCI, with regulators, key opinion leaders, persons with lived experience, patient and community advocacy organizations and the investment community, in order to discuss perspectives on current and future treatments, impact and support SCI disease awareness and clinical trial participation through the implementation of patient appropriate clinical endpoints, and importantly, broaden awareness of and investment capital into SCI. The 3rd SCIIS will be a fully virtual event, with interactive and on-demand sessions available starting on June 27, 2025.

LCTX

Lineage Cell Therapeutics And Christopher & Dana Reeve Foundation To Collaborate And Present 3Rd Annual Spinal Cord Injury Investor Symposium

AUBN

Auburn National Bancorp Q1 EPS $0.44 Up From $0.39 YoY, Sales $7.79M Up From $7.54M YoY

Wells Fargo analyst Zachary Fadem maintains Domino's Pizza (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NASDAQ">DPZ</a>) with a Equal-Weight and raises the price target from $420 to $445.

Wells Fargo Maintains Equal-Weight on Domino's Pizza, Raises Price Target to $445

Baird analyst David George maintains Comerica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMA#NYSE">CMA</a>) with a Outperform and lowers the price target from $80 to $75.

Baird Maintains Outperform on Comerica, Lowers Price Target to $75

Sunrise Realty Trust, Inc. ("SUNS" or "the Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUNS#NASDAQ">SUNS</a>), a commercial real estate lender on the Tannenbaum Capital Group ("TCG") Real Estate platform, today provided a preliminary estimate of distributable earnings for the quarter ended March 31, 2025, and disclosed other portfolio level information.
Distributable Earnings &amp; Book Value Per Share
SUNS' preliminary estimate of distributable earnings for the quarter ended March 31, 2025 is $0.30 to $0.32 per basic weighted average common share. This compares to distributable earnings of $0.30 for the quarter ended December 31, 2024. In addition, SUNS disclosed that it expects its book value per share to be $13.60 - $13.90 per share.
Portfolio and Originations
During the quarter ended March 31, 2025, the TCG Real Estate platform originated $212.5 million of loans, of which SUNS committed $147.5 million and funded $109.8 million of new and existing loans. As of March 31, 2025, the SUNS portfolio had $352.1 million of commitments with $233.4 million funded. As of April 18, 2025, the SUNS portfolio has $352.1 million of commitments with $235.4 million funded. Currently, the TCG Real Estate Platform has two signed, non-binding term sheets totaling $100 million in documentation, of which we expect SUNS to be allocated a portion.

Guidance

SUNS

SUNS' Preliminary Estimate Of Distributable Earnings For The Quarter Ended March 31, 2025 Is $0.30-$0.32 Per Basic Weighted Average Common Share; SUNS Disclosed That It Expects Its Book Value Per Share To Be $13.60-$13.90 Per Share

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) has reportedly pivoted its marketing for the Cybertruck as Elon Musk's EV giant rebrands the vehicle to showcase its utilitarian quotient.
What Happened: Targeting a more traditional pick-up truck marketing approach for the vehicle, Tesla has reworked the Cybertruck's page on the official website. The website now features visuals of the Cybertruck hauling construction material and a trailer, family outings, as well as visuals of the vehicle on rugged terrains — all activities one would expect a pick-up truck owner to do, <a href="https://www.businessinsider.com/tesla-cybertruck-revamp-working-man-f-150-2025-4">reported </a>Business Insider on Tuesday.
This is in stark contrast to the previous strategy, which showcased the Cybertruck as a futuristic vehicle with visuals of other planets like Mars. The report mentioned how the company has moved to position the Cybertruck to be &#8220;less DeLorean, more Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) F-150.&#8221;
However, the shift in approach may be difficult to put into practice. "Pitching it to truck people is more about the functionality,&#8221; an anonymous Tesla salesperson told the publication.
The salesperson also shared how traditional truck customers ask about the Cybertruck's towing capabilities as well as how much it can haul in the bed. Cybertrucks have been criticized for a lack of ruggedness in the past.
Tesla did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment.
Why It Matters: The shift in strategy comes in as Tesla has <a href="https://www.benzinga.com/markets/equities/25/04/44755221/tesla-unveils-new-cybertruck-long-range-trim-with-a-362-mile-range-and-reduced-features">released a cheaper version </a>of the Cybertruck priced at $62,490 with the Federal EV credit, as the company looks to boost <a href="https://www.benzinga.com/tech/25/04/44857987/tesla-experiences-151-decline-in-new-vehicle-registrations-in-california-report">dwindling sales figures</a> and appeal to a wider customer base.
Recently, Tesla properties like Superchargers as well as vehicles like the Cybertruck have been <a href="https://www.benzinga.com/trading-ideas/25/04/44829030/tesla-owners-face-new-challenge-amid-tariffs-vandalism-insurance-costs-going-up-twice-the-national-rate">subject to vandalism</a> in the U.S., which coincides with Musk's endorsement of right-wing political ideals and increasing involvement with the Trump administration.
Elsewhere, while Tesla still dominates the <a href="https://www.benzinga.com/25/04/44755934/us-q1-ev-sales-data-shows-106-yoy-growth-tesla-experiences-decline-but-still-dominates-domestic-ev-sales">domestic U.S. EV sector</a>, other brands are catching up with Musk's company, according to sales data, which shows an increase in adoption of EVs among drivers in the U.S.
Price Action: TSLA has experienced a 40.04% YTD decline in stock value. It currently trades for $227.42, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Check out more of Benzinga's Future Of Mobility coverage by <a href="https://www.benzinga.com/topic/mobility">following this link</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/04/44915873/tesla-settles-lawsuit-over-fatal-2021-crash-involving-model-y">Tesla Settles Lawsuit Over Fatal 2021 Crash Involving Model Y</a></li>
</ul>
Image Via Shutterstock

Tech

TSLA

Cybertruck Gets A Down-To-Earth Redesign As Tesla Shifts To Traditional Pickup Marketing Amid Poor Sales

Stephens &amp; Co. analyst Matt Olney reiterates BOK Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOKF#NASDAQ">BOKF</a>) with a Equal-Weight and maintains $124 price target.

BOKF

Stephens & Co. Reiterates Equal-Weight on BOK Financial, Maintains $124 Price Target

Press Releases

Broad Arrow Releases Video Featuring Ferrari 250 GT LWB California Spider Competizione Drive Head of Amelia Auction

Insurance

Hagerty Reports Full Year 2024 Results; Provides 2025 Outlook for Revenue and Profit Growth

Broad Arrow's Amelia Auction Continues 2025 Success with $61.7 Million in Total Sales

Entertainment

The Amelia Winners: 1938 Alfa Romeo 8C 2900 and 1967 Lotus 49 Earn Best of Show Accolades as Enthusiasts Celebrate Speed and Elegance

BROAD ARROW PRESENTS MOTORSPORT STARS AT CONCORSO D'ELEGANZA VILLA D'ESTE AUCTION

BROAD ARROW TO HOST EXCLUSIVE BMW SALE AT CONCORSO D'ELEGANZA VILLA D'ESTE

BROAD ARROW ADDS RARE RUF CTR YELLOWBIRD TO PORSCHE AUCTION IN PARTNERSHIP WITH AIR|WATER

BROAD ARROW ANNOUNCES 918 SPYDER WEISSACH AND CARRERA GT AS FINAL ENTRIES FOR PORSCHE AIR|WATER AUCTION

Greenwich Concours Announces Grand Marshal, Curated Vehicle Classes and Exclusive Reverie Premier Event for Coastal Luxury Showcase

Sports

BROAD ARROW PRESENTS DARIO FRANCHITTI MEMORABILIA IN ONLINE AUCTION TO BENEFIT SIR JACKIE STEWART'S RACE AGAINST DEMENTIA CHARITY

HGTY

Abacus Global Management, Inc. - Class A Common Stock

Abacus Global Management

AIFU

Arthur J. Gallagher

Aon plc Class A Ordinary Shares (Ireland)

Brown & Brown

The Baldwin Insurance Group, Inc. - Class A Common Stock

Baldwin Insurance

Cheche Group Inc. - Class A Ordinary Shares

Cheche Group

Crawford & Company Common Stock

eHealth

GoHealth

Goosehead Insurance, Inc. - Class A Common Stock

Goosehead Insurance

Hippo Holdings

Health In Tech, Inc. - Class A Common Stock

Health In Tech

Huize Holding Limited - American Depositary Shares

Huize Holding

Marsh & McLennan Companies, Inc. Common Stock

Marsh & McLennan Cos

Reliance Global Group, Inc. - Common Stock

Reliance Global Group

Ryan Specialty Holdings, Inc. Class A Common Stock

Ryan Specialty Hldgs

SelectQuote

TIAN RUIXIANG Holdings Ltd - Class A Ordinary Shares

Tian Ruixiang Holdings

TWFG

Waterdrop Inc. American Depositary Shares (each representing the right to receive 10 Class A Ordinary Shares)

Comments

Hagerty

Hagerty (HGTY) オプション

Hagerty (NYSE:HGTY) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル